Together these results suggest that SM6Met as monotherapy cannot compete with current SOC therapy at targeting ER+ breast cancer cell proliferation, however, SM6Met may prove just as effective as the SOC therapy at targeting pro-metastatic processes such as ER+ breast cancer cell invasion and colony formation, but not cancer cell migration. Here, ESR1 is linked to breast cancer.